Akums Drugs: Down 30%

 

  • Akums Drugs: Down 30%
  • CDMO is the biggest theme; select companies can grow 5 times in next 10 years: Madhusudan Kela
  • The Delhi-based contract development and manufacturing organisation (CDMO) 
  • Sandeep Jain, Managing Director of Akums Drugs said he expects the company's revenue to remain flattish for FY25. 
  • However, he will be able to maintain the margin in the CDMO business at around 15%.
  • About 78% of Akums' total revenue comes from the CDMO business.
  • Exports contribute around 5% of the company’s total revenue, and Jain said the aim is to maintain this level.
  • The company is also putting substantial effort into its marketing business to drive growth across other segments.
  • Akums is a pharmaceutical CDMO offering a comprehensive range of pharmaceutical products and services in India and overseas. 
  • The company has the largest capacity in the country. Its capacity utilisation stood at 40%, and can scale up to 60%.

Comments

Popular posts from this blog

Confidence Petroleum Forays into Hydrogen Cylinder Manufacturing

RSI Indicator for finding good value stocks?

Poonawalla Fincorp: I love stocks at 52L